Abstract Neutrophils play a major role in inflammation by releasing large amounts of reactive oxygen species (ROS) produced by NADPH oxidase (NOX) and myeloperoxidase (MPO). This ROS overproduction is mediated by phosphorylation of the NOX subunits in an uncontrolled manner. Therefore, targeting neutrophil subunits would represent a promising strategy to moderate NOX activity, lower ROS, and other inflammatory agents, such as cytokines and leukotrienes, produced by neutrophils. For this purpose, we investigated the effects of protectin DX (PDX)-a docosahexaenoic acid di-hydroxylated product which inhibits blood platelet aggregation-on neutrophil activation in vitro. We found that PDX decreases ROS production, inhibits NOX activation and MPO release from neutrophils. We also confirm, that PDX is an anti-aggregatory and anti-inflammatory agent by inhibiting both cyclooxygenase-1 and -2 (COX-1 and COX-2, E.C.
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Introduction
Chronic inflammation is involved in various diseases including atherosclerosis [1] , bowel disease [2, 3] , cancer [4] , cardiovascular diseases [5] , the metabolic syndrome [6] , and rheumatoid arthritis [7] . They all have in common [8] excessive production of pro-inflammatory mediators such as interleukin (IL)-1, IL-6, IL-8 [9] , granulocyte macrophage-colony stimulating factor (GM-CSF) [10] , leukotriene B 4 (LTB 4 ), platelet-activating factor (PAF), and tumor necrosis factor-a (TNF-a) [8] . Highly activated inflammatory cells such as neutrophils, monocytes and macrophages [11] , and production of reactive oxygen species (ROS) [12] [13] [14] [15] are common features. A major source of ROS at inflammation sites is the reduction of an oxygen molecule to a superoxide anion (O 2 -Á ) by neutrophil enzyme complex NADPH oxidase (NOX) [16] , and hypochloric acid (HOCl) produced by myeloperoxidase (MPO) from hydrogen peroxide [13] . In physiological situations, NOX activation in neutrophils is tightly regulated to avoid tissue damage. However, a dysregulation occurs in chronic inflammatory states where NOX subunits are strongly phosphorylated and translocated to the cell plasma membrane, resulting in highly active oxidase overproducing ROS [17] . Targeting NOX subunits to decrease ROS overproduction would then represent a strategy to develop new anti-inflammatory approaches. Dietary manipulation is a possible way to prevent inflammatory diseases that involve polymorphonuclear neutrophil (PMN) activation and oxidative stress. As a matter of fact, dietary long-chain n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, present in marine food, have been widely used. As an example, they have been shown to attenuate inflammation and neutrophil infiltration in an experimental model of colitis [18] . N-3 PUFA may be converted into active oxygenated derivatives named protectins and resolvins which may fight inflammation [19] . Moreover, conjugated double bond-containing PUFA, like conjugated linoleic (CLA) and linolenic (ClnA) acids have been reported to decrease the incidence of tumors in mice, to inhibit cell proliferation and invasion of cancer cells by promoting apoptosis [20] [21] [22] . We have previously found that punicic acid, a conjugated triene PUFA found in a high percentage (70 %) in pomegranate seed oil, exerts a potent anti-inflammatory effect through inhibition of TNFa-induced priming of neutrophil NOX, by targeting the p38MAPK/Ser 345 -p47 phox axis, and by decreasing neutrophil degranulation and MPO release [23] . On the other hand, oral administration of punicic acid or pomegranate seed oil to rats inhibits trinitrobenzene sulfonic acid (TNBS)-induced colitis and decreases ROSinduced tissue damage through a down regulation of neutrophil activation [23] .
Recently, our group identified new di-oxygenated derivatives from PUFA, called poxytrins, which inhibit blood platelet aggregation [24] . Among them, protectin DX (PDX) derived from DHA [25] shares some structure similarity with other conjugated triene fatty acids, like punicic acid and oleostearic acid. PDX is an isomer of protectin/neuroprotectin D1, which is known to have antiinflammatory properties [19, 26] . More recently, PDX (called PD1 isomer, even PD1 throughout the paper) has been shown to inhibit influenza virus replication [27] , which makes it a relevant molecule to fight this infectious disease. The aim of the present study was to test whether PDX may have an anti-inflammatory effect by modulating neutrophil activation. A second goal was to determine the precise anti-inflammatory potential of PDX through cyclooxygenase inhibition. We found that PDX decreases ROS produced by neutrophils stimulated with formylmethionyl-leucyl-phenylalanine (fMLF), and phorbol myristate acetate (PMA) in vitro, and partly inhibited neutrophil degranulation and MPO release by fMLF-triggered neutrophils. Also, PDX is an inhibitor of COX-1, as well as COX-2 which the activity is enhanced during inflammation, but fails to inhibit the 5-lipoxygenase pathway. Altogether, these effects provide evidence that PDX may be an anti-inflammatory agent acting through original mechanisms. 
Materials and Methods
Reagents and
PDX Synthesis
PDX was prepared as previously described [25] . Briefly, 200 lM DHA was incubated with sLOX in sodium-borate buffer (pH 9.0) on ice for 30 min, synthesized hydroperoxides were then reduced by NaBH 4 for 15 min, and the reduction step was stopped by adding acetic acid to pH 3.0. PDX was extracted by using a C18-Sep Pak cartridge, collected by reverse phase high performance liquid chromatography (RP-HPLC), and measured according to its UV absorbance.
Preparation of Human Neutrophils and Measurement of ROS Production
Human neutrophils were obtained from healthy donors using lipopolysaccharides (LPS)-free conditions by onestep purification on Polymorphprep dextran sedimentation as previously described [28] . Briefly, freshly drawn blood was added to cold dextran solution (0.1 mM dextran T500, 40 mM EDTA, 120 mM NaCl, pH 7.4) in screw-cap polypropylene tubes, and mixed gently. After at least 1 h on melting ice, the upper solution was collected and mixed with phosphate-buffered saline (PBS) pH 7.4. Cold Ficoll (density 1.077) was added carefully to the bottom of the tubes and were further centrifuged at 500g for 20 min at 4°C. After centrifugation, lymphocytes were removed and the pellets were re-suspended in cold PBS. Red cells were lysed by hypotonic shock. Neutrophils were then washed twice with PBS and kept on ice until analysis.
ROS production was measured with a luminol-amplified chemiluminescence method: human neutrophils were suspended in Hank's balanced salt solution (HBSS) containing 10 lM luminol, and pre-heated at 37°C in the thermostated chamber of the luminometer (Berthold-Biolumat LB937) prior to treatment with PDX. Neutrophils were then stimulated with PMA (0.162 mM) or 0.1 lM fMLF, for chemiluminescence recording.
Measurement of Released MPO from Neutrophils
The release of MPO was performed by measuring its activity in using the H 2 O 2 -dependent tetramethyl benzidine (TMB)-oxidation assay at 650 nm. Human neutrophils were suspended in HBSS and pre-heated at 37°C. The cells were treated with PDX, and then stimulated or not with 0.1 lM fMLF. Neutrophils were then centrifuged and MPO activity was measured in supernatants. Total MPO activity was expressed in mU/min relative to a standard curve established with known amounts of triton X-100-treated neutrophils.
Immunoblotting of MPO released by fMLF stimulated neutrophils was done with primary rabbit antibodies against MPO (dilution: 1/10,000), and with a horseradish peroxidase (HRP)-labeled-goat anti-rabbit antibody (dilution: 1/10,000). The reaction was measured by using enhanced chemiluminescence (ECL) reagents.
Detection of Ser 345 Phosphorylation in Neutrophils
Neutrophils were incubated with different concentrations of PDX for 20 min, then treated with 0.1 lM fMLF for 20 min. Cell proteins were denatured in Laemmli buffer [29] . The samples were analyzed by 10 % SDS-polyacrylamide gel electrophoresis (PAGE), and immunoblotting was done with primary rabbit antibodies against phospho-Ser 345 (dilution: 1/10,000) or against p47 phox (dilution: 1/5,000), then with HRP-labeled-goat anti-rabbit antibody (dilution: 1/10,000). The reaction was measured by using ECL reagents.
Measurement of 5-Lipoxygenase Activity in Neutrophils
Human neutrophils, suspended in a Tyrode-HEPES buffer containing 2 mM of Ca 2? , were pre-incubated with 1 lM PDX for 3 min at 37°C, and were then triggered with 1 lM of ionophore A23187 plus 10 lM of ARA for 10 min. The reaction was terminated by acidifying the medium to pH 3.0 with acetic acid. Oxygenated metabolites (5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-HETE), LTB 4 and its isomers) were then extracted by solid phase extraction on Sep-Pak C18-cartridges. They were analyzed by RP-HPLC on a Waters XBridge C18 column (4.6 9 250 mm, 3.5 lm) by using a linear solvent gradient (1 mL/min): solvent A was acetonitrile/water (10:90, v/v) pH 3.0, and solvent B was acetonitrile. Mono-hydroxylated conjugated diene and di-hydroxylated conjugated triene fatty acids were detected with a diode array detector at 235 and 270 nm, respectively.
GC-MS Measurement of COX-1 and COX-2 Activities
Commercial COX-1 and COX-2 were pre-incubated for 15 min in a 0.1 M Tris HCl buffer pH 8.0 with or without 0.5 or 5 lM of PDX, and incubated with 10 lM ARA as a substrate for 10 min. Albumin (45 g/L) was added to enhance the formation of prostaglandin (PG) D 2 and E 2 from PGH 2 at the end of incubation [30] . Reaction was stopped by acidification to pH 3.0 with acetic acid. PGD 2 and E 2 were then extracted by 10 volumes of diethyl ether. Deuterated PGD 2 and E 2 were used as internal standards for their quantification. Prostaglandins were derivatized into methoxime, pentafluorobenzyl ester and trimethysilyl ether, and further analyzed by NICI GC-MS. Selected ions corresponding to [M-181] -(loss of the PFB group): m/ z 524 for both derivatized PGD 2 and E 2 and m/z 528 for their corresponding deuterated internal standards, were used for their measurement.
Measurement of LPS-Induced COX Activities in Human Neutrophils
Human neutrophils were treated by LPS (100 ng/mL) in order to overexpress COX-2. After 4 h, cells were preincubated in the presence or absence of 10 lM PDX for 3 min at 37°C, and 10 lM radiolabelled ARA (333 Bq/ nmol) was added as a substrate for 10 min. After acidification to pH 3.0 with acetic acid, lipids were extracted by ten volumes of diethyl ether and separated by thin-layer chromatography (TLC). Radioactivity of extracted gel spots corresponding to PGD 2 and E 2 were measured by scintillation counting.
PDX Incorporation into Neutrophils 10 lM PDX was incubated with isolated neutrophils for 3 min at 37°C. Cells were washed twice with buffer containing 45 g/L fatty acid free albumin. After centrifugation at 500g for 20 min at 4°C, pellets were extracted using methanol/acidified water and PDX was measured by LC-MS/MS (AB Sciex, Qtrap 4500), using the double 15-lipoxygenase product of ARA (8, as an internal standard. Quantification was done using multiple reaction monitoring mode (MRM). Parent ions were m/ z 359 and m/z 335 and daughter ions m/z 153 and m/z 235 for PDX and 8,15-diHETE respectively.
Statistical Analysis
All results are expressed as means ± standard errors of the means (SEM) or means ± standard deviations (SD). One away ANOVA followed by Fisher's protected least significant difference (PLSD) post hoc test was used to assess differences between groups. P value of 0.05 was assumed to represent the level of significance. Statistical significance was determined by using two-tailed Student's t tests in case of comparison between two groups of values.
Results
PDX Inhibits fMLF and PMA-Induced Superoxide
Anion From Neutrophils PDX was tested on ROS production in response to PMA. In presence of PDX for 20 min, PMA-induced neutophil production of ROS was decreased. Our results (Fig. 1) show that in absence of PDX, PMA induced a marked ROS production compared to baseline (Fig. 1A) , and incubation of neutrophils with PDX prior to the addition of PMA, induced a significant decrease in ROS production (Fig. 1B) , indicating that PDX inhibited NOX activity, and/or scavenged the produced ROS. The effect of PDX was dose-dependent from 2.5 to 10 lM. At these concentrations, PDX did not affect PMN viability as determined by trypan blue exclusion test (not shown).
We then analyzed the effect of PDX on the neutrophil respiratory burst induced by 0.1 lM fMLF. Figure 2A shows that, similarly to the PMA experiments, the luminescence of neutrophils stimulated with fMLF is increased and lowered by PDX, in a dose-dependent manner, also from 2.5 to 10 lM (Fig. 2B) . In contrast, PDX had no effect on superoxide production by the in vitro xanthine/ xanthine oxidase system, and had no effect on H 2 O 2 availability as measured by the peroxidase-catalyzed reaction (data not shown). These data suggest that PDX scavenged neither the superoxide anion, nor H 2 O 2 .
PDX Inhibits fMLF-Induced MPO Release from Neutrophils
Neutrophil NOX produces superoxide anion (O 2 -) that is the source of other ROS. O 2 -is spontaneously dismutated into H 2 O 2 at acidic pH, within the phagosome or the extracellular medium. The release of MPO catalyzes the conversion of H 2 O 2 into the toxic molecule HOCl in presence of chloride ions [31] [32] [33] . Also, reaction between H 2 O 2 and OCl -produces singlet oxygen, another ROS. Therefore, the activation of NOX synergizes with MPO for inflammatory processes. The effect of PDX was then investigated on neutrophil release of MPO. Human neutrophils were incubated in HBSS medium in the presence or absence of PDX for 20 min at 37°C. After washing and centrifugation, PMN were stimulated with 0.1 lM fMLF, and MPO release was assessed by measuring its activity in supernatant of all samples. Figure 3A shows that MPO activity from neutrophils pre-treated with PDX and stimulated with 0.1 lM fMLF, was significantly decreased in a dose-dependent manner as compared to a control (neutrophils treated without PDX, but stimulated with fMLF). To test whether this inhibitory effect may reflect decreased neutrophil degranulation, or is related to decreased enzymatic activity, we performed a western blot analysis of the supernatant from fMLF-stimulated samples, using an antibody directed against human MPO. Results (Fig. 3B) show that the amount of MPO was lower in 5 lM and 10 lM PDX-treated neutrophils than in the control (neutrophils treated without PDX, but stimulated with fMLF), whereas we did not find any effect of PDX on the enzymatic activity determined in vitro on recombinant MPO activity (data not shown). Taken together our results suggest that PDX exerts an inhibitory effect on the stimulated neutrophil oxidative burst and degranulation.
PDX Inhibits fMLF-Induced p47
phox Phosphorylation on Ser 345 We had previously shown that production of ROS by NOX results from the phosphorylation of its cytosolic subunits, particularly p47 phox on Ser 345 . The effect of PDX on this process is shown in Fig. 4 . The level of phosphorylated 345 P-Ser on p47 phox has been corrected from the amount of total p47 phox , which shows that PDX significantly lowers the phosphorylation of this protein when induced by fMLF treatment of neutrophils (Fig. 4A, B) . Effect of PDX on COX-1 and COX-2 Activities
The inhibition of purified cyclooxygenases (COX-1 and COX-2) by 0.5 and 5 lM of PDX were assessed by GC-MS measurement of both PGD 2 and E 2 which represent the global prostaglandin synthesis after albumin addition and acidification that convert PGH 2 into PGD 2 and E 2 (see ''Materials and Methods''). Results reported in Table 1 show that 0.5 and 5 lM PDX significantly decreased prostaglandin production through COX-1 by around 55 and 75 %, respectively. Interestingly, the inhibition of COX-2 by PDX seems even more efficient as the decreased prostaglandin production through COX-2 attained 70 and 80 % in response to 0.5 and 5 lM PDX, respectively. This means that the decreased production of pro-inflammatory prostaglandins by PDX may substantially contribute in its antiinflammatory effects.
Effect of PDX on Prostaglandin Production in Human Neutrophils Treated by LPS
Neutrophils were treated by LPS in order to overexpress COX-2. Radiolabelled ARA was then used as a substrate for the neutrophil cyclooxygenase in the presence or absence of 10 lM PDX, in order to exclude the contribution of released endogenous ARA in response to LPS. COX activity was assessed by measuring the radioactive PGD 2 and E 2 as representatives of prostaglandin production. Results (Fig. 5) show that such a production was enhanced phox were quantified by densitometry, and the intensity of phosphorylated p47 phox was corrected for the amount of p47 phox (B). Data are representative of 3 independent experiments using cells from different healthy donors. Results are expressed as means ± SD (n = 3). Different letters indicate significant differences between the groups at the p \ 0.05 level (one away ANOVA followed by Fisher's PLSD test) by 121 % following the LPS treatment, compared to nonstimulated cells, reflecting the expected COX-2 overexpression. 10 lM PDX significantly decreased prostaglandin production by around 25 % in LPS-treated neutrophils. The inhibition by PDX was not visible in non-treated neutrophils compared to control (not shown). Table 2 show that even at 10 lM, PDX did not inhibit the 5-lipoxygenase pathway, meaning that the inhibition of the cyclooxygenase reported above is rather specific.
PDX Incorporation into Neutrophils
The IC 50 for the inhibition of isolated COX enzymes by PDX being much lower (less than 0.5 lM) than in neutrophils (more than 10 lM), studies on the uptake of PDX have been done. Incubation of neutrophils with 10 lM PDX led to low incorporation (8.5 ± 0.7 %) as measured by LC-MS/MS. No degradation products were detected, and the remaining PDX (not incorporated) was measured in the supernatant fraction.
Discussion
The present study shows that PDX inhibits both ROS production and MPO release by human neutrophils. Also, the inhibition of fMLF-induced activation of NOX results from the inhibition of the phosphorylation of p47phox on Ser 345 . Several cytokines, including TNF-a, are involved in many inflammatory states. As a matter of fact, anti-TNF-a antibodies are used to treat some severe forms of inflammatory bowel disease [34] . This cytokine primes the neutrophil ROS production that is a key process in inflammation [35] . Primed neutrophils have been reported in diverse inflammatory states [36, 37] . One molecular mechanism involved in this priming process is the phosphorylation of p47 phox on Ser 345 . Anti-inflammatory interventions could use nutritional approaches to decrease such a phosphorylation and subsequently ROS overproduction, without altering that one which is required for innate immunity and host defense. The present study shows that PDX, a double lipoxygenase product of DHA, is able to slow-down NOX activation and subsequent ROSderived oxidative stress. MPO activity was also decreased by PDX to the same extent. As MPO and ROS (especially H 2 O 2 ) generate toxic molecules at the inflammatory sites, Fig. 5 Effect of PDX on the production of PGD 2 and E 2 in human neutrophils treated or not by LPS. Human neutrophils (2 9 10 6 cells/ mL HBSS) were treated in the presence or absence of 100 ng/mL LPS for 4 h. Cells were then pre-incubated with and without 10 lM PDX for 3 min at 37°C and incubated with 10 lM radiolabelled ARA for 10 min. Lipids were extracted after acidification, and PGD 2 and E 2 , representative of prostaglandin production, were separated by TLC. Their corresponding spots were detected by dichlorofluorescein, scraped off and the radioactivity was counted. Results are expressed in nanomoles of PGD 2 and E 2 synthesized and represent the means ± SEM of 4 determinations. *p \ 0.05 as compared to control the inhibition by PDX supports the potential action of this DHA metabolite as an anti-inflammatory agent. However, this protective effect needs to be confirmed in vivo.
Other fatty acids may affect ROS production in neutrophils. Linoleic acid (LA), the main consumed fatty acid in western countries [38] , may act synergistically with TNF-a to affect ROS production [39, 40] . The LA product ARA can directly activate neutrophils [41] through enzymatic conversion into pro-inflammatory oxygenated metabolites such as LTB 4 and PGE 2 [42] [43] [44] . By contrast, n-3 PUFA such as EPA and DHA, provided by marine lipids, are oxygenated into less inflammatory and even antiinflammatory derivatives counteracting the effects of ARA-derived eicosanoids [45] . Indeed, Hardy et al. [46] have shown that pre-treatment with ARA, enhances fMLFor PMA-stimulated neutrophils, then inducing more superoxide anion production than in non ARA-enriched cells. In contrast, a recent study reported that EPA and DHA could increase the response of neutrophils to TNF-a [47] . None of these in vitro and in vivo experiments have addressed the molecular mechanism that might explain the increased ROS production.
Nutritional doses of EPA and DHA have been used in humans to prevent inflammatory states, and to lower the level of circulating inflammation markers [45] . The inhibitory effect of PDX on prostaglandin synthesis by either sheep COX-1 or human recombinant COX-2 is quite relevant in this respect, especially at 0.5 lM. This was also observed to a lesser extent in neutrophils treated by LPS. However, this inhibition is in the same order if we consider that only 8 % of PDX was incorporated into the neutrophils after 10 lM incubation. This means that PDX would be more relevant when produced inside neutrophils through their own 15-LOX.
In addition to the COX-1 inhibition, already observed in relation with the inhibition of platelet aggregation [24] , PDX appears to be an even more potent inhibitor of COX-2 which is the inducible enzyme, although detectable at low levels in most normal tissues. It becomes abundant in activated macrophages and other cells at sites of inflammation. The anti-inflammatory potential of PDX is quite specific since it fails to inhibit the 5-lipoxygenase pathway. Therefore, PDX appears to be an original anti-inflammatory agent able to play a protective role in chronic inflammatory diseases.
We conclude that PDX inhibits fMLF-induced ROS production by targeting the neutrophil p47 phox /NOX axis and MPO release as well. Besides its inhibitory effects on platelet aggregation through inhibition of COX-1, that is confirmed against purified COX-1, PDX inhibits COX-2 and then could protect against inflammation. It might be used for the prevention and treatment of various inflammatory diseases. However, further in vivo studies are needed to confirm those in vitro findings.
